However, monotarget compounds were examined in one hypertension model only, specific routes of administration (i.a. or i.c.v.)were used, and the CB1R antagonist rimonabant, which had been examined in long-term clinical studies, was withdrawn from the market because of its undesirable side effects. Here, CNR1 is linked to Hypertension.